Skip to main content
Springer logoLink to Springer
. 2017 Apr 26;34(5):1234. doi: 10.1007/s12325-017-0538-3

Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

László Gulácsi 1,, Valentin Brodszky 1, Petra Baji 1, Fanni Rencz 1, Márta Péntek 1,2
PMCID: PMC5427141  PMID: 28447267

Erratum to: Adv Ther DOI 10.1007/s12325-017-0522-y

The authors of this manuscript have noticed a mistake since publication of their manuscript.

In the original publication, the “Total RTX consumption per patient (mg)” in Table 1, was incorrectly published as 1814.00. The correct value of “Total RTX consumption per patient (mg)” should read as 11,814.00.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Footnotes

The online version of the original article can be found under doi:10.1007/s12325-017-0522-y.


Articles from Advances in Therapy are provided here courtesy of Springer

RESOURCES